Specific antisera for the radioimmunoassay of estradiol-3-sulfate. 1985

T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera

Antisera were prepared against two types of estradiol-3-sulfate-bovine serum albumin (BSA) conjugates. The haptens were coupled to BSA through the C-6 position in the steroid molecule by the glutaraldehyde (A) or the carbodiimide method (B). In comparison the antiserum produced by method A had a high affinity for estradiol-3-sulfate (Ka = 5.64 X 10(8) M-1); that produced by method B had an even higher affinity (Ka = 2.62 X 10(9) M-1). Furthermore the latter had no significant cross-reaction with other estrogen sulfates (less than 3.83%), and no cross-reaction with other steroids (less than 0.03%). The former revealed a little cross-reactivity with some of related steroids.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004966 Estrogens, Conjugated (USP) A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. Conjugated Equine Estrogen,Conjugated Estrogen,Estrogenic Substances, Conjugated,Progen,Carentil,Climarest,Climopax,Congest,Conjugated Equine Estrogens,Conjugated Estrogens,Dagynil,Estro-Feminal,Estrogenic Hormones, Conjugated,Estrogens, Conjugated,Femavit,Oestro-Feminal,Oestrofeminal,Prelestrin,Premarin,Presomen,Progens,Transannon,Conjugated Estrogenic Hormones,Conjugated Estrogenic Substances,Equine Estrogen, Conjugated,Equine Estrogens, Conjugated,Estro Feminal,Estrogen, Conjugated,Estrogen, Conjugated Equine,Oestro Feminal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
May 1976, FEBS letters,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
January 1973, Experientia,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
October 1983, Chemical & pharmaceutical bulletin,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
September 1982, Rinsho byori. The Japanese journal of clinical pathology,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
July 1985, Clinica chimica acta; international journal of clinical chemistry,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
August 1978, Journal of steroid biochemistry,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
October 1974, Journal of animal science,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
January 1988, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
September 2005, The Journal of steroid biochemistry and molecular biology,
T Tanaka, and N Suguro, and Y Shiratori, and A Kubodera
February 1977, Steroids,
Copied contents to your clipboard!